Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a reshaped chemo combo tame lymphoma with fewer side effects?

NCT ID NCT07739654

Disease control Sponsor: King Edward Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 31, 2026 · Last updated Aug 11, 2026 · Updated 2 times

Summary

This Phase 3 trial compares a modified version of the standard DHAP chemotherapy regimen against the original in adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The modified regimen spreads out the cisplatin and cytarabine doses over several days, aiming to reduce kidney damage and other severe side effects while keeping the treatment effective. About 74 participants will be randomly assigned to receive either the modified or standard DHAP, and researchers will measure how well the lymphoma responds and how tolerable the treatment is.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A modified chemotherapy regimen (DHAP) that splits cisplatin and cytarabine into smaller doses over several days, instead of giving them as a single large dose.
What this could lead to
If the modified DHAP works as well as the standard but with fewer side effects, it could become a gentler, possibly outpatient, option for people with relapsed or refractory DLBCL.
What could go wrong
This is a relatively small trial, and the modified regimen might not be as effective as the standard. Chemotherapy still carries risks like kidney damage and low blood counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 74 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed relapsed or refractory DLBCL * Adults ≥ 18 years * At least one prior line of therapy for lymphoma * ECOG performance status 0-2 * Ability to provide informed consent and comply with study requirements * Adequate organ function: * Hematologic: ANC ≥ 1,000 cells/mm³, Platelets ≥ 75,000 cells/mm³ * Renal: Serum creatinine ≤ 1.5 × ULN * Hepatic: Total bilirubin ≤ 1.5 × ULN, AST/ALT ≤ 2.5 × ULN (if no liver metastases) Exclusion Criteria: * History of other malignancies within last 5 years (except non-melanoma skin cancer or localized prostate cancer) * Pregnant or breastfeeding women * Significant uncontrolled medical conditions (e.g., cardiovascular disease, uncontrolled diabetes) * Receipt of investigational agents within 30 days prior to enrollment * Known severe allergic reactions to DHAP components (dexamethasone, cytarabine, cisplatin) * Concurrent anti-cancer treatments (chemotherapy, radiotherapy) during study period

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DLBCL - diffuse large B cell lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

B-cell neoplasm diffuse large B-cell lymphoma interdigitating dendritic cell sarcoma relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DLBCL - diffuse large B cell lymphoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Mayo Hospital

    RECRUITING

    Lahore, Punjab Province, 54000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.